A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

NCT05773105 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: Cadonilimab+regorafenib

Sponsor

Sun Yat-sen University